このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Windtree Therapeutics 将来の成長

Future 基準チェック /06

Windtree Therapeutics の収益は、年間 26.2% 減少すると予測されています。EPS は、年間増加すると予測されています10.2%。

主要情報

-26.2%

収益成長率

10.2%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	03 Jan 2024

今後の成長に関する最新情報

Recent updates

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Dec 06

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Jul 06

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Jun 09

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Feb 09

業績と収益の成長予測

NasdaqCM:WINT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-35	-30	-30	1
12/31/2025	N/A	-30	-27	-27	1
12/31/2024	N/A	-22	-19	-19	1
3/31/2024	N/A	-6	-14	-14	N/A
12/31/2023	N/A	-20	-13	-13	N/A
9/30/2023	N/A	-25	-13	-13	N/A
6/30/2023	N/A	-24	-13	-13	N/A
3/31/2023	N/A	-35	-15	-15	N/A
12/31/2022	N/A	-39	-19	-19	N/A
9/30/2022	N/A	-43	-21	-21	N/A
6/30/2022	N/A	-47	-22	-22	N/A
3/31/2022	N/A	-67	-25	-24	N/A
12/31/2021	N/A	-68	-24	-24	N/A
9/30/2021	N/A	-62	-24	-23	N/A
6/30/2021	N/A	-63	-27	-26	N/A
3/31/2021	N/A	-35	-26	-26	N/A
12/31/2020	N/A	-33	-26	-25	N/A
9/30/2020	N/A	-32	-26	-26	N/A
6/30/2020	N/A	-31	-22	-22	N/A
3/31/2020	0	-27	-22	-21	N/A
12/31/2019	0	-27	-25	-25	N/A
9/30/2019	1	-43	-26	-25	N/A
6/30/2019	1	-40	-25	-25	N/A
3/31/2019	2	-37	-22	-22	N/A
12/31/2018	2	-35	-16	-16	N/A
9/30/2018	2	-9	-14	-14	N/A
6/30/2018	1	-13	-14	-14	N/A
3/31/2018	1	-17	-16	-16	N/A
12/31/2017	1	-25	N/A	-21	N/A
9/30/2017	2	-34	N/A	-23	N/A
6/30/2017	3	-35	N/A	-28	N/A
3/31/2017	2	-38	N/A	-32	N/A
12/31/2016	2	-39	N/A	-34	N/A
9/30/2016	2	-43	N/A	-34	N/A
6/30/2016	1	-56	N/A	-33	N/A
3/31/2016	1	-57	N/A	-34	N/A
12/31/2015	1	-55	N/A	-34	N/A
9/30/2015	2	-56	N/A	-36	N/A
6/30/2015	2	-45	N/A	-39	N/A
3/31/2015	3	-45	N/A	-40	N/A
12/31/2014	3	-44	N/A	-41	N/A
9/30/2014	2	-45	N/A	-41	N/A
6/30/2014	1	-46	N/A	-40	N/A
3/31/2014	0	-44	N/A	-40	N/A
12/31/2013	0	-45	N/A	-40	N/A
9/30/2013	1	-40	N/A	-39	N/A
6/30/2013	0	-41	N/A	-39	N/A

アナリストによる今後の成長予測

収入対貯蓄率: WINT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: WINT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: WINT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: WINTの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: WINT来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: WINTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Windtree Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$3.00

Price target decreased to US$5.50

Price target decreased to US$8.25

Recent updates

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering.

Windtree Therapeutics Regains Compliance with Nasdaq

Windtree Therapeutics Approves 1-for-18 Reverse Stock Split and Expects Compliance with Listing Requirements of the $1.00 Minimum Bid Price Requirement by The Nasdaq Capital Market

Windtree Therapeutics, Inc. (NasdaqCM:WINT) acquired All of the assets of Varian Biopharmaceuticals, Inc.

Windtree Therapeutics, Inc. announced delayed annual 10-K filing

Windtree Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Revenue and earnings growth

Windtree Therapeutics, Inc. Announces the Start of Patient Dosing in Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.054024 million.

New major risk - Share price stability

Windtree Therapeutics, Inc. Appoints Jamie McAndrew as Controller, Chief Accounting Officer and Principal Accounting Officer

Windtree Therapeutics, Inc. Is Developing A Multi-Asset Franchise of Its Novel Serca2a Activators

Windtree Therapeutics, Inc. Appoints Mark Strobeck to its Board of Directors

Windtree Therapeutics, Inc. Announces Chief Financial Official Officer Changes

Nasdaq Grants Windtree Therapeutics 180-Day Extension to Regain Compliance

Price target decreased to US$3.00

Windtree Therapeutics, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2022

Windtree Therapeutics, Inc. Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (Seismic) Published in the European Journal of Heart Failure

Windtree Therapeutics, Inc. Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

Windtree Therapeutics, Inc. Reports Impairment for the Second Quarter Ended June 30, 2022

Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value

Windtree Therapeutics Receives Non-Compliance Letter from Nasdaq

Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid

Windtree Therapeutics, Inc. Announces Not Stand for Re-Election of Evan Loh from Board

Windtree Therapeutics, Inc., Annual General Meeting, Jun 07, 2022

Price target decreased to US$5.50

Windtree Therapeutics, Inc. Announces Positive Topline Results from Its Phase 2 Seismic Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Completes Enrollment in its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome

Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)

Windtree Therapeutics, Inc. Announces Results of U.S. Hospital Claims Data Analysis Showing Hospital Inpatient Mortality and Length of Hospital Stay for Cardiogenic Shock Patients

Independent Chairman of the Board recently bought US$95k worth of stock

Price target decreased to US$8.25

Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions

Independent Non-Executive Director Bruce Peacock has left the company

Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable

Independent Chairman of the Board recently bought US$354k worth of stock

New 90-day low: US$4.94

Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?

Windtree Therapeutics, Inc. Announces Executive Changes

Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development

Windtree Therapeutics, Inc.(NasdaqCM:WINT) dropped from S&P TMI Index

Windtree Therapeutics, Inc. Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$4.98

Windtree Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients

Windtree Therapeutics, Inc. Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19

New 90-day low: US$5.94

Earnings released

New 90-day high - US$9.90

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘